Patents by Inventor Stuart A. Aaronson

Stuart A. Aaronson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5512434
    Abstract: A method for the identification of related polypeptides, using an function-based selection criterion, is disclosed. A novel human phosphatase, and nucleotide sequences coding therefor, identified by the aforementioned method and designated VHR, is also disclosed.
    Type: Grant
    Filed: December 14, 1992
    Date of Patent: April 30, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stuart A. Aaronson, Donald P. Bottaro, Toshio Ishibashi, Toru Miki
  • Patent number: 5480968
    Abstract: A DNA fragment distinct from the epidermal growth factor receptor (EGFR) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNA. Characterization of the cloned DNA fragment mapped the region of v-erbB homology to three exons with closest homology of 64% and 67% to a contiguous region within the tyrosine kinase domains of the EGFR and erbB-2 proteins, respectively. cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB family, prompting designation of the new gene as erbB-3. It was mapped to human chromosome 12 ql 11-13 and was shown to be expressed as a 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased erbB-3 expression, as in the case of EGFR and erbB-2, plays a role in some human malignancies.
    Type: Grant
    Filed: November 10, 1992
    Date of Patent: January 2, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Matthias H. Kraus, Stuart A. Aaronson
  • Patent number: 5468468
    Abstract: Potent neutralizing monoclonal antibodies to the human .alpha. PDGF receptor (.alpha. PDGFR) and fragments thereof are described. These monoclonal antibodies specifically bind to an epitope on .alpha. PDGFR, inhibits PDGF binding with PDGF, antagonizes PDGF, and does not bind .beta. PDGFR receptor. A hybridoma cell line producing such a monoclonal antibody, methods of in vivo imaging of a pathological conditions and methods of inhibiting the growth of a neoplasia expressing .alpha. PDGFR, which use these monoclonal antibodies are also described. In vitro assays for detecting the presence of .alpha. PDGFR and for evaluating the binding affinity of a test compound are also described.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: November 21, 1995
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: William J. LaRochelle, Jacalyn Pierce, Roy A. Jensen, Stuart A. Aaronson
  • Patent number: 5183884
    Abstract: A DNA fragment distinct from the epidermal growth factor receptor (EGF-R) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNA. Characterization of the cloned DNA fragment mapped the region of v-erbB homology to three exons with closest homology of 64% and 67% to a contiguous region within the tyrosine kinase domains of the EGF-R and erbB-2 proteins, respectively. cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB family, prompting designation of the new gene as erbB-3. It was mapped to human chromosome 12q11-13 and was shown to be expressed as a 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased erbB-3 expression, as in the case of EGF-R and erbB-2, plays a role in some human malignancies.
    Type: Grant
    Filed: December 1, 1989
    Date of Patent: February 2, 1993
    Assignee: United States of America
    Inventors: Matthias H. Kraus, Stuart A. Aaronson
  • Patent number: 4820631
    Abstract: Specific deletion mutants of ras p21 gene and specific monoclonal antibodies which recognize specific regions of the ras p21 protein have been prepared. A kit for detecting the presence of specific ras p21 proteins and their levels in a body sample has been described.
    Type: Grant
    Filed: July 30, 1986
    Date of Patent: April 11, 1989
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Juan C. Lacal, Stuart A . Aaronson